No takes yet. Share an insight, caveat, or question.
Preliminary study demonstrates that IL-17A monoclonal antibody reduces chronic graft versus host disease severity in mice, suggesting a potential treatment strategy.
Li et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: